Publicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (5)

2013

  1. Pegvisomant and cabergoline combination therapy in acromegaly

    Pituitary, Vol. 16, Núm. 1, pp. 101-108

2009

  1. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy

    European Journal of Endocrinology, Vol. 160, Núm. 4, pp. 535-542

2008

  1. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population

    Clinical Endocrinology, Vol. 68, Núm. 6, pp. 942-950

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326

2003

  1. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage

    Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481